Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22699635 | 0.76 | EPHX2 (0.55) | PDE3BPDE3AMAOAMAOBEPHX2 | |
| SCHEMBL21089938 | 0.76 | PDE3B (0.46) | PDE3BPDE3AMAOAMAOBEPHX2 | |
| SCHEMBL21053191 | 0.75 | PDE3B (0.42) | PDE3BPDE3A | |
| SCHEMBL22686131 | 0.75 | MGAM (0.30) | — | |
| SCHEMBL21055029 | 0.74 | MEN1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21054112 | 0.73 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL21090094 | 0.73 | PDE3B (0.46) | PDE3BPDE3AMAOAMAOBEPHX2 | |
| SCHEMBL22686147 | 0.72 | NR3C2 (0.36) | CYP11B1CYP11B2ALDH1A1MAPTKMT2A | |
| SCHEMBL7998823 | 0.69 | MAOB (0.53) | PDE3BPDE3AMAOAMAOBEPHX2 | |
| SCHEMBL590514 | 0.69 | MAOB (0.49) | PDE3BPDE3AMAOAMAOBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PDE3B 1119/4885PDE3A 1137/4885MAOA 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.